La douleur et l'inflammation en tant que médiateurs de l'effet du traitement au tofacitinib sur la fatigue des patients atteints de spondylarthrite ankylosante : Une analyse de médiation
Rheumatol Ther 2023;10(4):1073–1087 doi 10.1007/s40744-023-00570-0
Kristensen, et al. used mediation modelling to show that tofacitinib indirectly improved fatigue symptoms via back pain and morning stiffness. This study was carried out using FACIT-F- and BASDAI Q1-based models to determine the relationship between these variables.
This modelling study by Kristensen, et al. used data from two tofacitinib trials: one phase 2 and one phase 3. Both studies were interventional, randomised, placebo-controlled, parallel,
quadruple-masking clinical trials.
Keywords:
